Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. develops and commercializes biotechnology medicines for serious diseases across eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disease, neurological disease, hematologic conditions, infectious disease and rare disease. News about REGN commonly covers marketed products and pipeline programs such as EYLEA, EYLEA HD, Dupixent, Praluent, Libtayo, Kevzara, Otarmeni and investigational therapies developed through antibody, genetic medicine and RNA-based approaches.
Recurring company updates include financial results, FDA and European regulatory approvals, clinical trial data, label expansions, collaboration and licensing activity, product-access and pricing arrangements, share repurchase authorizations and corporate responsibility recognition. Regeneron's disclosures also frequently address its Sanofi collaboration around Dupixent and its use of proprietary technologies such as VelocImmune in drug discovery.
Regeneron (NASDAQ: REGN) reached an agreement with the U.S. government on April 23, 2026 to lower certain drug prices and expand access. Key terms include free U.S. access to Otarmeni, lowering Medicaid prices tied to other developed countries, aligning future U.S. prices to that country group, Praluent availability via TrumpRx.gov, three years of tariff relief, and a >$9 billion U.S. manufacturing and R&D investment commitment.
Regeneron (NASDAQ: REGN) announced FDA accelerated approval of Otarmeni (lunsotogene parvec-cwha), the first and only gene therapy for OTOF-related severe-to-profound sensorineural hearing loss, indicated for pediatric and adult patients with molecularly confirmed biallelic OTOF variants. Regeneron will provide Otarmeni for free in the U.S.
Approval was based on CHORD trial results showing 80% primary-endpoint responders at 24 weeks and 42% of evaluable participants achieving normal hearing at longer follow-up; continued approval may require confirmatory trial data.
Regeneron (NASDAQ: REGN) and Sanofi announced FDA approval of Dupixent (dupilumab) for children aged 2–11 with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamines.
The approval, effective April 22, 2026, is based primarily on the LIBERTY-CUPID program and includes pharmacokinetic data from a single-arm pediatric trial; safety was consistent with prior indications.
Regeneron (NASDAQ: REGN) reported Phase 3 NIMBLE results for cemdisiran showing rapid, deep and sustained disease control in generalized myasthenia gravis (gMG) with subcutaneous dosing every 12 weeks.
At week 24 cemdisiran vs placebo showed a 2.3-point placebo-adjusted MG-ADL improvement (p<0.001) and a 2.8-point placebo-adjusted QMG improvement (p=0.002). U.S. regulatory application submitted Q1 2026; EU filings planned for 2026.
Regeneron (NASDAQ: REGN) will webcast management presentations at two investor conferences in May and June 2026. Sessions are scheduled for BofA Securities Health Care Conference on May 12, 2026 at 10:00 a.m. PT (1:00 p.m. ET) and Goldman Sachs Global Healthcare on June 8, 2026 at 2:00 p.m. ET.
Webcasts, replays, and transcripts will be available via the company's Investors & Media page and archived for at least 30 days.
Regeneron (NASDAQ:REGN) and Telix announced a strategic collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies on a 50/50 cost and profit-sharing basis.
Key terms include a $40 million USD upfront payment to Telix for four initial programs, optional expansion to additional programs, potential aggregate milestone payments up to $2.1 billion USD, low double-digit royalties, and joint development of radio-diagnostics to support patient selection and response assessment.
Regeneron (NASDAQ: REGN) and Sanofi announced that the European Commission approved Dupixent (dupilumab) for treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2–11 years with inadequate response to H1 antihistamines and naïve to anti-IgE therapy.
The approval relies on the LIBERTY-CUPID program, combining adult Phase 3 efficacy data and pediatric CUPIDKids safety and pharmacokinetic data, and expands Dupixent's EU pediatric indications to under 12 across four type 2 inflammation diseases.
Regeneron (NASDAQ: REGN) announced a strategic collaboration with TriNetX to access TriNetX’s de-identified EHR network of approximately 300 million patients (about 170 million in the U.S.). Regeneron gains an exclusive opportunity to link RGC genomic and proteomic cohorts to this phenotypic dataset.
The deal enables expansion of Regeneron Genetics Center’s EHR-linked database, supports AI training for digital health solutions, and includes a Regeneron investment of up to $200 million. Data matching will follow applicable privacy laws including HIPAA and GDPR.
Regeneron (NASDAQ: REGN) announced FDA approval extending EYLEA HD (aflibercept) dosing intervals up to every 20 weeks (≈5 months) for wAMD and DME after one year of successful response, based on 96-week data from pivotal PULSAR and PHOTON trials.
Of patients completing week 96, 71% (wAMD) and 72% (DME) reached ≥16-week intervals; 47% (wAMD) and 44% (DME) reached ≥20-week intervals. Label now includes 96-week efficacy and safety; prefilled syringe review has an April 2026 target action date.
Regeneron (NASDAQ: REGN) will report first quarter 2026 financial and operating results on Wednesday, April 29, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:30 AM ET that day.
According to the company, the webcast will be available on its Investors and Media page and telephone participation requires advance registration; a replay and transcript will be archived on the company website for at least 30 days.